Systematic evaluation and meta-analysis of the prognosis of down-staging human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma using cetuximab combined with radiotherapy instead of cisplatin combined with radiotherapy.

Is it necessary to completely reject the use of cetuximab instead of cisplatin combined with radiotherapy? Although the analysis above showed a significant trend of impairment in the OS of HPV + patients for at least 2 years, subgroup analysis revealed no significant difference in OS between the use of cetuximab + radiotherapy and cisplatin + radiotherapy in early stage non-pharyngeal tumors in patients with no history of smoking or ≤10 packs/year of smoking under the criteria of the 7th edition of the UICC/AJCC and without lymphatic metastases involved.

also in 9,775 other papers